Zejing Pharmaceuticals (688266.SH) released the semi-annual report for 2024, during which the company achieved revenue of 2...
According to the report released by Zejing Pharmaceuticals (688266.SH) on the 2024 semi-annual report, the company realized revenue of 0.241 billion yuan, a year-on-year increase of 9.44%; the net loss attributable to the shareholders of the listed company was 66.5361 million yuan; the net loss attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 72.3712 million yuan; with a basic loss per share of 0.25 yuan/share.
As of June 30, 2024, the company's Pemigatinib Tosylate tablets for the treatment of advanced liver cancer and progressive, locally advanced or metastatic radioiodine refractory differentiated thyroid cancer have been included in the medical insurance catalog, and the recombinant human coagulation factor has been approved for listing. Due to the continuous investment required for team expansion and market expansion for Pemigatinib Tosylate tablets, the short time of approval for recombinant human coagulation factor, and other products still in the application for listing or in the research and development stage requiring significant R&D investment, the company has not yet made a profit and there is an accumulated unrecovered loss.